LSS

CompletedPhase 3

Latino Semaglutide Study

A Randomized Latino Semaglutide 2.4mg Study

Lead sponsor

Loma Linda University

Asset

Semaglutide

GLP-1 agonist

Listed sites

Recruiting sites

Actual enrollment

119

Study population

Obesity / overweight

Eligibility highlights

•BMI ≥30

Primary endpoint

•Body weight, absolute change (kg)

Registered trial locations

Locations reported to ClinicalTrials.gov for this trial snapshot. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT05087342

Org study ID5210364

Timeline

Milestones

Study first posted2021-10-21actual

Study start2022-12-13actual

Primary completion2024-05-29actual

Study completion2024-05-29actual

Last update posted2024-10-15actual

Assets

Investigational agents

Semaglutide

Who this study enrolls

Obesity / overweight

Who can enroll

Minimum age18 Years

Maximum age75 Years

SexAll

Healthy volunteersNot accepted

Inclusion criteria

•Self-identify as being of Hispanic/Latino ethnicity

•BMI >30

•Age 18-75 years old

•Able to provide informed consent before any trial related activities

Exclusion criteria

•Current cancer treatment

•Diabetes, Type 1 or Type 2

•Eating disorders

•Medication use targeting the GPL-1 system

•In the last 30 days, attempted to lose weight by lifestyle modification alone or with the use of anti-obesity medications resulting in more than 5 pounds of weight loss.

•History of bariatric surgery

•Use of obesogenic medications (including but not limited to steroids, haloperidol, clozapine, risperidone, olanzapine, amitriptyline, imipramine, paroxetine, and lithium) which cannot be substituted or stopped.

•Pregnant or planning to become pregnant in the next 8 months

•Genetic disorders and/or physical or mental handicaps that would limit participation in the study and/or the intensive lifestyle intervention.

•Any contraindication to semaglutide 2.4 mg including personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia Syndrome Type 2, hypersensitivity to semaglutide 2.4 mg or any product components.

•Any known or suspected allergy to semaglutide 2.4 mg or related products

•Previous participation in this trial, either initial screening or group randomization

Endpoints (2)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Coverage by outcome category

Weight & body composition

Other clinical outcomes

Weight & body composition

1 endpoint

Primary/protocol endpoint

Assessment of weight loss.

Time frame:Change between baseline and final study visit, seven months post baseline.

Body weight, absolute change (kg)

change from baseline, improvement

Other clinical outcomes

1 endpoint

Secondary/protocol endpoint

Food Addiction Assessment

Time frame:Change between baseline and month four of treatment.

change from baseline, improvement

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2

Snapshot dateJuly 6, 2026

Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)

Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 6, 2026 snapshot.